Cargando…
Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats
OBJECTIVE: Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506271/ https://www.ncbi.nlm.nih.gov/pubmed/37723593 http://dx.doi.org/10.1186/s13075-023-03153-0 |
_version_ | 1785107087331688448 |
---|---|
author | Partain, Brittany D. Bracho-Sanchez, Evelyn Farhadi, Shaheen A. Yarmola, Elena G. Keselowsky, Benjamin G. Hudalla, Gregory A. Allen, Kyle D. |
author_facet | Partain, Brittany D. Bracho-Sanchez, Evelyn Farhadi, Shaheen A. Yarmola, Elena G. Keselowsky, Benjamin G. Hudalla, Gregory A. Allen, Kyle D. |
author_sort | Partain, Brittany D. |
collection | PubMed |
description | OBJECTIVE: Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites and Gal3 binds carbohydrates to extend IDO’s joint residence time. In this study, we evaluated IDO-Gal3’s ability to alter OA-associated inflammation and pain-related behaviors in a rat model of established knee OA. METHODS: Joint residence was first evaluated with an analog Gal3 fusion protein (NanoLuc™ and Gal3, NL-Gal3) that produces luminescence from furimazine. OA was induced in male Lewis rats via a medial collateral ligament and medial meniscus transection (MCLT + MMT). At 8 weeks, NL or NL-Gal3 were injected intra-articularly (n = 8 per group), and bioluminescence was tracked for 4 weeks. Next, IDO-Gal3s’s ability to modulate OA pain and inflammation was assessed. Again, OA was induced via MCLT + MMT in male Lewis rats, with IDO-Gal3 or saline injected into OA-affected knees at 8 weeks post-surgery (n = 7 per group). Gait and tactile sensitivity were then assessed weekly. At 12 weeks, intra-articular levels of IL6, CCL2, and CTXII were assessed. RESULTS: The Gal3 fusion increased joint residence in OA and contralateral knees (p < 0.0001). In OA-affected animals, both saline and IDO-Gal3 improved tactile sensitivity (p = 0.008), but IDO-Gal3 also increased walking velocities (p ≤ 0.033) and improved vertical ground reaction forces (p ≤ 0.04). Finally, IDO-Gal3 decreased intra-articular IL6 levels within the OA-affected joint (p = 0.0025). CONCLUSION: Intra-articular IDO-Gal3 delivery provided long-term modulation of joint inflammation and pain-related behaviors in rats with established OA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03153-0. |
format | Online Article Text |
id | pubmed-10506271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105062712023-09-19 Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats Partain, Brittany D. Bracho-Sanchez, Evelyn Farhadi, Shaheen A. Yarmola, Elena G. Keselowsky, Benjamin G. Hudalla, Gregory A. Allen, Kyle D. Arthritis Res Ther Research OBJECTIVE: Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites and Gal3 binds carbohydrates to extend IDO’s joint residence time. In this study, we evaluated IDO-Gal3’s ability to alter OA-associated inflammation and pain-related behaviors in a rat model of established knee OA. METHODS: Joint residence was first evaluated with an analog Gal3 fusion protein (NanoLuc™ and Gal3, NL-Gal3) that produces luminescence from furimazine. OA was induced in male Lewis rats via a medial collateral ligament and medial meniscus transection (MCLT + MMT). At 8 weeks, NL or NL-Gal3 were injected intra-articularly (n = 8 per group), and bioluminescence was tracked for 4 weeks. Next, IDO-Gal3s’s ability to modulate OA pain and inflammation was assessed. Again, OA was induced via MCLT + MMT in male Lewis rats, with IDO-Gal3 or saline injected into OA-affected knees at 8 weeks post-surgery (n = 7 per group). Gait and tactile sensitivity were then assessed weekly. At 12 weeks, intra-articular levels of IL6, CCL2, and CTXII were assessed. RESULTS: The Gal3 fusion increased joint residence in OA and contralateral knees (p < 0.0001). In OA-affected animals, both saline and IDO-Gal3 improved tactile sensitivity (p = 0.008), but IDO-Gal3 also increased walking velocities (p ≤ 0.033) and improved vertical ground reaction forces (p ≤ 0.04). Finally, IDO-Gal3 decreased intra-articular IL6 levels within the OA-affected joint (p = 0.0025). CONCLUSION: Intra-articular IDO-Gal3 delivery provided long-term modulation of joint inflammation and pain-related behaviors in rats with established OA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03153-0. BioMed Central 2023-09-18 2023 /pmc/articles/PMC10506271/ /pubmed/37723593 http://dx.doi.org/10.1186/s13075-023-03153-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Partain, Brittany D. Bracho-Sanchez, Evelyn Farhadi, Shaheen A. Yarmola, Elena G. Keselowsky, Benjamin G. Hudalla, Gregory A. Allen, Kyle D. Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats |
title | Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats |
title_full | Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats |
title_fullStr | Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats |
title_full_unstemmed | Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats |
title_short | Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats |
title_sort | intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male lewis rats |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506271/ https://www.ncbi.nlm.nih.gov/pubmed/37723593 http://dx.doi.org/10.1186/s13075-023-03153-0 |
work_keys_str_mv | AT partainbrittanyd intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats AT brachosanchezevelyn intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats AT farhadishaheena intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats AT yarmolaelenag intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats AT keselowskybenjaming intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats AT hudallagregorya intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats AT allenkyled intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats |